Artificial intelligence

My vision

The next leap in biology will be a tool, and the people who need it most should be the ones building it.

Schematic in three bands. Top, every leap in biology was a tool: microscope 1665, DNA sequencing 1977 after 312 years, single-cell RNA sequencing 2009 after 32 years, spatial transcriptomics 2016 after 7 years, then AI-built tools in the 2020s, months apart and many at once. Middle, how AI-built tools happen: scientists from many fields (pathologist, immunologist, chemist, clinician, data scientist) adopt AI and share ideas through collaboration, which feeds AI-built tools; the tools let scientists see what was invisible and produce new data, which loops back as new questions. Bottom, where it lands: digital pathology, drug discovery, many diseases, healthcare impact.

I am excited about this technology, and we have not scratched the surface. What AI will mean for science is mostly unbuilt. The tools available today are early versions of something much larger, and the people best placed to build the next ones, scientists at the bench, have barely started. That gap is the interesting part.

Right now most of the attention goes to reading the data we already have: digging into large and complicated datasets, finding the patterns inside them, building models that predict an outcome. That work is good, and I do plenty of it. A dataset that took a team years to produce can now be questioned from many angles in a week. Deeper analysis of existing data is real progress, and it should continue.

The bigger change comes when working scientists use AI to build their own tools. A tool built at the bench can see things in the data that no instrument was looking for, and can pull out measurements that were never an option before. A scientist at the bench knows which question is stuck. Give that person the ability to build, and the tool arrives shaped to the question, sometimes very niche, sometimes very big. Question to tool to new data to better question: that loop is where I think the field moves.

History supports this. Every leap in biology came from a tool. The microscope showed us cells. DNA sequencing let us read the instructions inside them. Spatial transcriptomics, which maps which genes are switched on at each spot in a slice of tissue, turned a flat image into a map of behaviour. Each was an instrument, and the understanding followed it. AI will produce a generation of instruments, most of them software.

AI is already at work in life science. It reads pathology slides and ranks drug candidates, and it does this in software alone, with no new hardware. That is a good start. The bigger change is still ahead. Discovery moves at the speed of its machinery. Every field can only go as far as the instruments it knows how to build, and those instruments are bounded by what we already understand. I believe AI will push past that boundary. It will help us design instruments we could not have engineered on our own, and reach questions that have sat out of range. This is my view from life science. I do not think it stops there. Any industry held back by its hardware faces the same wall, up to and including travel through space. Wherever the tool is the bottleneck, AI will help us build a better one.

The obstacle is adoption. Scientists are busy people whose day-to-day work does not pause. A small number use AI seriously, and most of them are bioinformaticians, who understand the science deeply. The limit is structural: they answer questions using data that other people have already generated. When the scientists designing the experiment can also build the tool, the data itself changes, and so do the questions worth asking.

So my aim is practical: raise adoption among working scientists, and build partnerships that make building a tool the normal first move. Some problems have waited years, and some decades, because the work needed to attack them was too slow for any one team. Those bottlenecks set the pace of a field. The limiting factor, in my view, will be people who know a field well enough to see which bottleneck matters and know the tools well enough to remove it. I want to be one of them. I am optimistic about where this goes, and I would like to hear from anyone building toward the same thing.

Where the bottleneck really is

The loudest progress in AI for drug discovery is in molecule design. Protein structures can be predicted, and chemistry can be generated and screened in software. Investment has followed, because this is where the data are clean and the feedback is fast. But that is not where most drugs fail. They fail because the target, the biomarker or the patient group was wrong, and a well-designed molecule cannot fix a wrong idea about the disease.

The hard problem is telling cause from correlation. Large genomic and biobank datasets are full of signals that travel with a disease without driving it. A signature can separate patients who do well from those who do badly, and still say nothing about who will respond to a drug. The evidence that would settle these questions often exists. It is scattered across papers written for other purposes, trial records, lab notebooks, and negative results that never get published.

So I think the next gains will come less from generating more candidates and more from judging evidence well. From the bench, I want four things from an AI research tool: provenance down to the cohort, the assay and the species; negative results treated as evidence; a clear line between an association and an experiment that changed something; and honest confidence, including where sources disagree.

This is also why the scientist has to stay in the loop. Industry leaders now describe AI agents as capable interns whose work must be checked. Checking that work needs someone who knows how the tissue was collected, what the controls were, and which statistic answers which question. Verification, more than generation, is becoming the scarce skill. It is the work I do every day, and it is where I think working scientists can make these tools better.

AI in cancer research

AI is part of every working day for me, and it is the most consequential tool I have used. In my own work, most of the hours used to go to the tasks between the ideas: cleaning data, writing and checking analysis code, finding the three papers that matter in a hundred. AI now takes on much of that. It changes what one researcher can attempt, and it changes what I expect of the next decade.

Illustration: a gold thread runs from complex data to predictive models to AI-built tools, then through a larger central step labelled evidence and verification, cause, not just correlation, where a scientist examines linked documents and data through a magnifying lens. From there it fans out to digital pathology, drug discovery and across diseases, and meets at healthcare impact, shown as three human outlines.

Recognition and tools

In 2026 my application to Anthropic's AI for Science program, for a project built around AI at every step, was accepted. I work with Anthropic's current models through Claude Code and the API, in Python and R in VS Code, and I build small agents of my own for the repeated work: data curation, literature screening, and the checks I want run every time. I have also built a cross-linked knowledge base for a whole research program, and a set of specialist agents: ethics drafting, cytometry, histology, assay design, and an adversarial audit that tests a result before release. Earlier: a scholarship from the Australian Centre for AI in Medical Innovation (2025) and a top-ten place at the Protoaxiom Challenger Summit (2024).

Building toward the same thing?